

Id	Research Ethics Committee Reference Number	Name of Trial	Target number of patients available	Target number of patients	Date Agreed to recruit target number of patients available	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time	Comments
20255	10/H0721/66	UBIOPRED: Unbiased BIOMarkers for the Prediction of Respiratory Disease Outcomes. Assessment of adults with severe asthma	Available	87	Available	30/04/2014	Closed - In Follow Up	Y	
20256	10/H0806/82	International Study of Incident Cancer (ISICA) - Breast Cancer and Diabetes	Available	10	Available	31/12/2011	Closed - Follow Up Complete	Y	
20257	11/H1003/90	A Sideguard Coronary Sidebranch Registry: A post market registry to observe the clinical outcomes of the Bare Metal Sideguard? Coronary Sidebranch stent in de novo	Available	10	Available	04/09/2014	Open	N/A	
20258	11/WA/0142	A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long-term Phase III Trial Assessing the Safety and Efficacy of 50 ?g and 100?g/day of eprotriome in Patients with	Available	50	Available	20/02/2014	Withdrawn	N/A	Abandoned
20259	11/NS/0020	Efficacy of ranolazine in patients with coronary artery disease (CAD)	Available	12	Available	28/12/2012	Closed - In Follow Up	Y	
20260	10/H0402/38	A randomised, double-blind, placebo-controlled, parallel-group, multicentre study to evaluate cardiovascular outcomes during treatment with lixisenatide in type 2 diabetic	Available	6	Available	03/04/2014	Closed - In Follow Up	N/A	
20261	08/H1010/26	Open label study of Isavuconazole in the treatment of patients with Aspergillosis and Renal Impairment or of patients with Invasive Fungal Disease caused by rare molds, yeasts or	Available	2	Available	31/10/2013	Closed - Follow Up Complete	N	Did not recruit anyone, now closed to recruitment
20262	12/NW/0006	A phase III, double blind, randomised study to evaluate safety and efficacy of BAL8557 versus Voriconazole for primary treatment of Invasive Fungal Disease caused by 2Aspergillus	Available	2	Available	01/04/2013	Closed - Follow Up Complete	N	Did not recruit anyone, now closed to recruitment
20263	11/LO/2025	The Impact of Omalizumab Treatment in UK Clinical Practice (APEX II study)	Available	20	Available	26/07/2013	Open	N/A	

20264	12/EM/0242	A randomised, double-blind, parallel group, dose-ranging study to evaluate the efficacy and safety of three different totally daily doses of fluticasone propionate inhaled from a new	Available	11	Available	01/11/2013	Open	N/A	
20265	11/NW/0690	Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)	Available	8	Available	09/01/2014	Withdrawn	N/A	Abandoned
20266	12/SC/0469	Odyssey	Available	5	Available	01/07/2014	Closed - In Follow Up	Y	
20267	11/NW/0201	Simultaneous development of a questionnaire for use as an endpoint in clinical research in 3 languages: Evaluation of gas-related symptoms and their associated discomfort in the	Available	3	Available	31/07/2012	Closed - In Follow Up	Y	
20268	12/WM/0194	A randomised, double-blind, placebo-controlled, phase 3 study to evaluate efficacy, safety and tolerability of JNJ-27018966 in the treatment of patients with diarrhea-predominant irritable	Available	7	Available	15/12/2013	Open	N/A	
20269	12/NW/0145	A prospective, observational study in Europe to evaluate the direct and indirect economic burden of moderate to severe Irritable Bowel Syndrome with Constipation (IBIS-C Study)	Available	20	Available	25/11/2013	Open	N/A	
20270	08/H0711/45	A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after ERCC1 stratification in patients with advanced/metastatic non-	Available	45	Available	01/08/2016	Closed - In Follow Up	Y	
20271	11/LO/0054	NGR015:Randomized double-blind phase III study of NGR-hTNF plus best investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural	Available	12	Available	01/08/2016	Closed - In Follow Up	Y	
20272	12/NW/0002	A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Treatment of Physician's Choice in Subjects with Advanced Non-Small Cell	Available	15	Available	01/05/2016	Closed - In Follow Up	Y	
20273	12/NW/0431	A multi-centre, open-label, adaptive, randomised study of Palifosfamide-tris, a novel DNA Crosslinker, in combination with Carboplatin and Etoposide (PaCE) chemotherapy versus	Available	15	Available	01/09/2015	Closed - In Follow Up	Y	

20274	12/WM/0159	A randomised, phase 2, multi-centre, double-blind, placebo controlled study evaluating the efficacy and safety of MetMab in combination with either Bevacizumab + Platinum +	Available	4	Available	31/10/2013	Closed - In Follow Up	Y	
20275	12/EE/0371	A multi-centre, randomised, active-controlled efficacy and safety study comparing extended duration Betrixaban with standard of care Enoxaparin? for the prevention of venous	Available	20	Available	01/11/2014	Open	N/A	
20276	12/NE/0181	A phase 3, randomised, single-blind, controlled trial of topical fibrocaps in intraoperative surgical haemostasis	Available	60	Available	30/04/2013	Open	N/A	
20277	12/EM/0284	A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial.	Available	2	Available	21/04/2016	Open	N/A	
20278	12/WN/0341	A double-blind, randomised, placebo-controlled, multicentre study assessing the impact of additional LDL-cholesterol reduction on major cardiovascular events when	Available	22	Available	08/04/2018	Open	N/A	
20279	13/NW/0054	A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100mg of VPR700 by inhalation in reducing the frequency and severity of cough	Available	20	Available	30/09/2013	Open	N/A	
20280	11/SC/0372	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic Nephropathy	Available	5	Available	05/04/2014	Open	N/A	K - Closed - not recruited - we did come in very late to this study with a short recruitment period, which was further reduced with little notice.
20281	13/SC/0312	Screening for Advanced Heart Failure Treatment (SEE - HF)	Available	25	Available	04/07/2014	Open	N/A	
20282	13/NI/0044	A study to measure Serum Periostin, asthma-related biomarkers and response to Prednisolone in adult and adolescent patients with severe oral corticosteroid-dependent	Available	9	Available	31/03/2014	Open	N/A	
20283	13/NW/0215	A double blind, randomized, placebo controlled phase II study to assess the efficacy of recPRAME +AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant	Available	4	Available	01/08/2020	Open	N/A	

20284	13/LO/0501	A Phase 2, randomized, dose-ranging study to assess the safety and anti-cytomegalovirus (CMV) activity of Maribavir versus Valganciclovir for the treatment of CMV infections in	Available	12	Available	10/06/2014	Open	N/A	
20285	13/WN/0234	A prospective, Multicentre, Controlled Study of implant-based breast reconstruction, measuring the safety, effectiveness and cost consequences, of Immediate	Available	10	Available	31/07/2015	Open	N/A	
20286	12/NW/0693	Azole Therapy in Cystic Fibrosis (ATCF): Efficacy of Itraconazole and of Voriconazole in patients with cystic fibrosis and presenting with persistent positive sputums for Aspergillus.	Available	12	Available	01/01/2016	Open	N/A	
20287	13/NW/0462	Randomised, double-blind, dose-finding Phase II study to assess the efficacy of APD403 in the prevention of nausea and vomiting caused by cisplatin - or anthracycline /	Available	12	Available	31/12/2014	Open	N/A	
20288	13/EM/0230	A Phase II Randomised, Double-Blind, Placebo-Controlled, Multicenter study of VS6063 in subjects with Malignant Pleural Mesothelioma	Available	10	Available	28/02/2015	Open	N/A	
20289	13/NW/0586	A study to Assess RepeatTreatment Efficacy and Safety of Rifaximin 550mg TID in Subjects with irritable Bowel Syndrome with Diarrhoea (IBS-D)	Available	40	Available	30/12/2015	Open	N/A	
20290	13/YH/0232	A randomised double-blind (sponsor-unblind) placebo controlled, cross-over study to investigate the efficacy, effect on cough reflex sensitivity, safety, tolerability and pharmacokinetics	Available	16	Available	30/05/2014	Open	N/A	
20291	13/SC/0348	A randomised, open label Phase II study evaluating LY2875358 plus Erlotinib and LY2875358 monotherapy in MET diagnostic positive NSCLC patients with acquired resistance to Erlotinib	Available	3	Available	28/11/2015	Open	N/A	
20292	13/LO/0219	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER)	Available	3	Available	20/08/2017	Open	N/A	
20293	13/LO/1121	A randomized, controlled phase 2 study evaluating LY2875358 plus Erlotinib versus Erlotinib as first-line treatment in Metastatic non-small cell lung cancer patients with activating EGFR	Available	6	Available	30/12/2020	Open	N/A	

20294	13/NE/0094	Phased RF Evaluation of Acute Pulmonary Vein Isolation in Paroxysmal AF with new GENius UI and PVAC GOLD.	Available	10	Available	04/08/2014	Open	N/A	
20295	13/NW/0715	The Role of GABA _B Receptor Mechanisms in Cough: Effect of Lesogaberan, Baclofen and Placebo on Experimentally Induced Cough Responses in Healthy Controls	Available	15	Available	02/12/2014	Open	N/A	